Utah · Medicare · Part D: GLP-1 drugs for weight, diabetes and heart risk
Does Medicare Cover Wegovy & Zepbound in Utah? (2026-27)
Yes, for now. Since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge lets eligible people with Medicare drug coverage get Wegovy, Zepbound or Foundayo for weight management for $50 a month, and CMS has said it runs through December 31, 2027. It has strict rules on who qualifies, it does not count toward your Part D cap, and it sits beside a second change on January 1, 2027, when Medicare's negotiated price for Ozempic, Rybelsus and Wegovy takes effect. Here is how both work for a Utah household, what they cost, and what CMS's files show about GLP-1 use in Utah.
The bottom line
- Medicare now covers some GLP-1 drugs for weight loss, temporarily. The Medicare GLP-1 Bridge covers Wegovy (injection or tablet), Zepbound (KwikPen only) and Foundayo (tablet) for $50 a month, from July 1, 2026 through December 31, 2027.
- You need Part D and a qualifying BMI and condition. A BMI of 35+, or 30+ with certain heart, blood pressure or kidney conditions, or 27+ with prediabetes or past heart attack, stroke or artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease go through their Part D plan instead.
- The $50 sits outside your Part D cap. It does not count toward the deductible or the $2,400 out-of-pocket limit in 2027: a year on the Bridge is $600 on top of your other drugs.
- Ozempic's Medicare price drops January 1, 2027. The negotiated price for Ozempic, Rybelsus and Wegovy is $274 for a 30-day supply, 71% below the 2024 list price of $959.
- Utah's Medicare population uses Mounjaro more and Ozempic less than the nation. In 2024, 2.68% of Utah Part D enrollees filled Ozempic against 3.59% nationally, while 2.06% filled Mounjaro against 1.64%.
For most of Medicare's history the answer to “will Medicare pay for a weight-loss drug?” was a flat no: the law that created Part D excludes drugs used for weight loss. That left GLP-1 drugs covered only when prescribed for something else, such as type 2 diabetes or, since 2024, heart risk. The GLP-1 Bridge is a demonstration that works around that exclusion, paid outside the normal Part D benefit, for a defined group of people and a defined period. Open Enrollment, which runs October 15 to December 7, 2026, is the time to check that your 2027 drug coverage fits whichever route applies to you.
What is the Medicare GLP-1 Bridge, and which drugs does it cover?
Medicare.gov describes the Bridge as a temporary program “available nationwide” to certain people with Medicare drug coverage. CMS launched it on July 1, 2026, and in an April 21, 2026 memo to drug plans it extended the program “through December 31, 2027” while it delays the Part D portion of a related model, called BALANCE, that was meant to start in 2027. What replaces the Bridge after 2027 has not been announced.
| Question | Medicare GLP-1 Bridge |
|---|---|
| Drugs covered | Wegovy (injection or tablet), Zepbound (KwikPen only; single-dose Zepbound pens and vials are not covered), Foundayo (tablet) |
| What you pay | $50 for a one-month supply, “no matter your income level” |
| Counts toward your Part D deductible or yearly cap? | No |
| Can be spread out under the Medicare Prescription Payment Plan? | No |
| Which drug coverage qualifies | A stand-alone Part D plan; a Medicare Advantage plan with drug coverage (HMO, HMO-POS, local and regional PPO); a Special Needs Plan; an employer or union group waiver plan; the LI NET program. Not private fee-for-service plans, cost plans or PACE when that is your only Medicare coverage |
| Prior authorization | Your doctor completes it when asked; an approval covers refills and dose changes through December 31, 2027, unless you switch GLP-1s |
| Program dates | July 1, 2026 through December 31, 2027 |
Sources: Medicare.gov, Weight loss drugs; Medicare.gov fact sheet, Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234, June 2026); CMS, Status Update on the BRIDGE Demo and BALANCE Model in Part D for CY2027 (April 21, 2026).
Who qualifies for the GLP-1 Bridge?
Medicare's fact sheet lists four requirements, and you must meet all of them. You have Medicare Part D coverage. You are not already eligible to get a GLP-1 through your drug plan. You do not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. And you are at least 18 and meet one of three weight tests when you start therapy:
| Body mass index (BMI) | Plus at least one of these |
|---|---|
| 35 or higher | Nothing else needed |
| 30 or higher | Heart failure with preserved ejection fraction (diastolic heart failure); uncontrolled high blood pressure; chronic kidney disease, stage 3a or higher |
| 27 or higher | Prediabetes; a previous heart attack or stroke; peripheral artery disease with symptoms (blocked arteries in the legs or arms) |
Source: Medicare.gov, Weight loss drugs, “Who's eligible.”
Two exclusions catch people off guard. If your Part D plan has ever paid for a GLP-1 for you, for any reason, you stay with your plan. The fact sheet says you “need to keep getting your GLP-1 drug through your plan,” and it defines GLP-1s by ingredient: semaglutide, tirzepatide, orforglipron, dulaglutide and liraglutide. And if you have type 2 diabetes, sleep apnea or fatty liver disease, the Bridge is not your route, because Medicare.gov says your Part D plan “might cover your GLP-1s” for those conditions. In that case the plan's formulary, tier and prior authorization rules decide what you pay, and the cost counts toward your cap.
If you are already paying cash for a GLP-1 outside your Medicare coverage, Medicare.gov's eligibility tool says you may still qualify for the Bridge if you have Part D. If you do not have Part D, you are not eligible until you get it.
How do you get a GLP-1 through the Bridge?
- Talk with your doctor about whether a GLP-1 is appropriate for you and whether you meet the BMI and condition rules. This is a medical decision; the drugs have side effects and are not right for everyone.
- Your doctor sends a prescription for Wegovy, Zepbound KwikPen or Foundayo to your pharmacy.
- The pharmacy confirms you are eligible. It may ask for your Medicare Number, or look it up with the last four digits of your Social Security Number.
- Your doctor submits a prior authorization form to Medicare and certifies that you are using the drug as part of a diet and exercise program.
- Medicare mails you a letter confirming coverage. You pay $50 for each one-month supply; refills on the same drug do not need a new approval, even when the dose changes.
Source: Medicare.gov fact sheet, Medicare GLP-1 Bridge (CMS Product No. 12234). Questions about eligibility or a prior authorization: 1-800-MEDICARE (1-800-633-4227), TTY 1-877-486-2048.
A caution Medicare.gov repeats on this page: if anyone calls offering GLP-1 drugs through Medicare and asks for your Medicare Number, hang up and call 1-800-MEDICARE. The program runs through your doctor and pharmacy. Our guide to Medicare fraud and scams in Utah covers how to report one.
What changes for Ozempic and other GLP-1s in Part D in 2027?
For people who get a GLP-1 through their Part D plan, mostly for diabetes, the bigger news is the price underneath the plan. Ozempic, Rybelsus and Wegovy are one of the 15 drugs in the second round of Medicare drug price negotiation, and CMS's fact sheet lists a negotiated price of $274 for a 30-day supply starting January 1, 2027, against a 2024 list price of $959. Semaglutide was the largest of the 15 by spending: about $15 billion in Part D gross costs in 2024, for about 2,282,000 people.
Sources: CMS, Negotiated Prices for Initial Price Applicability Year 2027 fact sheet; CMS, Medicare Part D Prescribers by Geography and Drug, 2024, Utah rows (gross drug cost divided by 30-day-equivalent fills); Medicare.gov, Part D costs; Medicare.gov fact sheet 12234.
The negotiated price applies by package, so it varies by dose and form. CMS's examples: a 4 mg Ozempic pen at $276.78, and a box of four 2.4 mg Wegovy pens at $385.63. What you pay still depends on your plan. A plan that charges 25% coinsurance charges it on a lower price; a plan with a flat copay may not change your copay at all. Check each plan's 2027 drug list and cost for your exact drug and dose during Open Enrollment, which our 2027 Part D changes guide walks through.
How many Utahns on Medicare use GLP-1 drugs?
CMS's Part D prescriber file counts everyone in Medicare drug coverage who filled each drug, by the state of the prescriber. In 2024, 9,839 Utah Part D enrollees filled Ozempic, up 37% from 7,159 in 2023, and 7,546 filled Mounjaro, 3.1 times the 2023 count. Against average 2024 Part D enrollment of 366,921 in Utah and 54,375,198 nationally, Utah's prescribers lean toward tirzepatide (Mounjaro) more than the nation and toward semaglutide (Ozempic) less.
Part D enrollees with at least one claim for the drug in 2024, divided by average 2024 Part D enrollment; Utah bars solid, national bars lighter. A person who filled two of these drugs is counted under each. Sources: CMS, Medicare Part D Prescribers by Geography and Drug, 2024; CMS, Medicare Monthly Enrollment.
| Drug | Part D use in 2024 | Utah enrollees, 2023 | Utah enrollees, 2024 | Utah gross cost, 2024 | U.S. enrollees, 2024 |
|---|---|---|---|---|---|
| Ozempic, semaglutide (injection) | Type 2 diabetes | 7,159 | 9,839 | $57,908,665 | 1,951,892 |
| Mounjaro, tirzepatide (injection) | Type 2 diabetes | 2,405 | 7,546 | $49,999,863 | 894,243 |
| Trulicity, dulaglutide (injection) | Type 2 diabetes | 6,782 | 6,163 | $40,828,594 | 788,414 |
| Rybelsus, semaglutide (tablet) | Type 2 diabetes | 1,076 | 1,152 | $6,467,541 | 309,850 |
| Wegovy, semaglutide (injection) | Heart risk with obesity or overweight (Part D since 2024) | Not published | 153 | $824,846 | 52,936 |
Utah rows are claims written by Utah prescribers; gross cost is total paid by plans, enrollees and others before rebates. “Not published” means the file has no Utah row for that year. Zepbound had no Utah row in 2024. Source: CMS, Medicare Part D Prescribers by Geography and Drug, 2023 and 2024.
Together these five drugs accounted for $156 million in Utah Part D gross costs in 2024. The tiny Wegovy line is the point of the Bridge: before July 2026, Part D could cover Wegovy only for its heart-risk indication, so 153 Utahns filled it in 2024. The 2024 file predates the Bridge, and because Bridge claims are paid outside the Part D benefit, they may not appear in this file at all. Utah has 392,485 people in Medicare drug coverage as of June 2026, out of 490,235 on Medicare.
How common is obesity in Utah, county by county?
CDC's PLACES estimates put adult obesity (a BMI of 30 or more) at about 31.0% statewide in 2023, weighting the 29 county estimates by adult population, against 32.8% nationally. That statewide figure hides a wide spread: 13 of Utah's 29 counties are above the national rate, from 37.6% in Tooele County to 19.8% in Summit County. These figures cover all adults, not only people 65 and over, so they describe the communities rather than the Medicare population.
| County | Adult obesity, 2023 | County | Adult obesity, 2023 |
|---|---|---|---|
| Tooele | 37.6% | Box Elder | 32.6% |
| Sevier | 36.4% | Juab | 32.6% |
| Uintah | 35.5% | Duchesne | 31.6% |
| Iron | 35.3% | Emery | 30.6% |
| Carbon | 35.0% | Salt Lake | 29.9% |
| Weber | 34.7% | Utah | 29.7% |
| Wayne | 34.3% | Sanpete | 29.2% |
| San Juan | 34.2% | Garfield | 28.6% |
| Millard | 34.1% | Beaver | 28.5% |
| Kane | 33.3% | Grand | 28.3% |
| Daggett | 33.1% | Cache | 27.9% |
| Washington | 33.1% | Morgan | 25.0% |
| Piute | 33.0% | Wasatch | 24.3% |
| Davis | 32.7% | Summit | 19.8% |
| Rich | 32.7% |
Crude prevalence of obesity among adults 18 and older, model-based estimates from the 2023 Behavioral Risk Factor Surveillance System; ranked highest to lowest, reading down the left columns then the right. Source: CDC, PLACES: Local Data for Better Health, County Data (2025 release). Small-county estimates are less precise.
Along the Wasatch Front, Weber County (34.7%) is above the national rate and Davis County (32.7%) is about level with it, while Salt Lake (29.9%) and Utah County (29.7%) are below it. Washington County, where many Utahns retire, is at 33.1%. A BMI of 30 alone does not qualify anyone for the Bridge; it is the starting line for the middle tier, which also requires a heart, blood pressure or kidney condition.
What else does Medicare cover for weight management?
- Obesity behavioral therapy (Part B). With a BMI of 30 or more, Part B covers a BMI screening and behavioral counseling on diet and exercise from your primary care provider, in a primary care setting. You pay nothing if the provider accepts assignment, and Medicare.gov says you must meet weight-loss requirements for the counseling to continue.
- The Medicare Diabetes Prevention Program (Part B). For people with prediabetes lab results and a BMI of 25 or more (23 or more if Asian) who have never had diabetes or ESRD: 16 weekly coaching sessions over six months and six monthly follow-ups, at no cost to you from an approved supplier.
- Medicare Advantage extras. Many plans add fitness memberships or nutrition benefits. These vary by plan and change each year, so read the plan's Evidence of Coverage, not the brochure.
Our guide to Medicare insulin and diabetes costs in Utah covers the diabetes side of these benefits in more detail.
A St. George example: one couple, two GLP-1 routes in 2027
A retired couple in St. George both take a GLP-1. He has type 2 diabetes and takes Ozempic, which his Part D plan covers. She has a BMI of 31 and uncontrolled high blood pressure, no diabetes, and has never had a GLP-1 through her plan, so she qualifies for the Bridge and takes Wegovy. The figures below use the 2027 standard Part D benefit design for him; real plans often use copays instead, so treat his number as an illustration.
| Item | Him: Ozempic through his Part D plan | Her: Wegovy through the GLP-1 Bridge |
|---|---|---|
| Price basis | $274 a month negotiated price, $3,288 a year | Flat $50 a month |
| What applies | The $700 deductible, then 25% coinsurance, capped at $2,400 | No deductible; no cap |
| Estimated 2027 cost for this drug | $1,347 | $600 |
| Counts toward the Part D cap? | Yes | No; her other prescriptions still count toward her own cap |
| Can be spread out monthly? | Yes, under the Medicare Prescription Payment Plan | No, but it is already a flat monthly amount |
Illustrative, not a price quote. Excludes Part D premiums and other drugs; assumes the full 30-day negotiated price for every month and a plan using the standard benefit. Sources: CMS, Negotiated Prices for Initial Price Applicability Year 2027; Medicare.gov, Part D costs; Medicare.gov fact sheet 12234.
Together that is about $1,947 for the two drugs in 2027, or roughly $162 a month, before premiums. For a couple living on Social Security and savings, that belongs in the 2027 budget as a fixed line, with one known risk: her $50 price is promised only through December 31, 2027. A retirement income plan should carry a what-if line for 2028, because nobody yet knows whether the cost then will be a Part D cost, a higher one, or no coverage at all. Our guide to the retirement income gap in Utah shows how to build that kind of line into a plan.
What should a Utah retiree do about GLP-1 coverage this fall?
- Check that you have Part D for 2027. The Bridge requires it. If you have none, Open Enrollment (October 15 to December 7, 2026) is when you can add a stand-alone plan or a Medicare Advantage plan with drug coverage for January 1, 2027. A late enrollment penalty may apply if you went without creditable coverage.
- If you take a GLP-1 for diabetes, look up your exact drug and dose on each plan's 2027 drug list: the tier, any prior authorization or quantity limit, and the cost after the $274 negotiated price for semaglutide takes effect.
- If weight is the reason, ask your doctor whether you meet the Bridge rules, and do not let anyone but your doctor or pharmacy handle the request.
- Budget the $50 a month outside your Part D cap, and pencil in a 2028 scenario, since the program ends December 31, 2027 unless CMS extends it.
- Read your Annual Notice of Change for formulary changes to your GLP-1 before December 7.
- Call Utah SHIP at (877) 424-4640 for unbiased help comparing your options at no cost, or 1-800-MEDICARE about Bridge eligibility.
We help Utah retirees compare how Medicare drug plans and Medicare Advantage plans cover their prescriptions, including GLP-1 drugs, and how those costs fit into a retirement income plan. Plain English, no pressure. Education, not advice. We do not offer every plan available in your area.
Talk to a planner →Frequently asked questions
Does Medicare cover Wegovy or Zepbound for weight loss?
Yes, for now, through a temporary program. Since July 1, 2026 the Medicare GLP-1 Bridge has covered Wegovy (injection or tablet), Zepbound (KwikPen only) and Foundayo (tablet) for weight management for eligible people with Medicare drug coverage, for a $50 copayment for a one-month supply. CMS says the Bridge runs through December 31, 2027. Your doctor must send the prescription, complete a prior authorization when asked, and certify that you are using the drug alongside a diet and exercise program.
Who qualifies for the Medicare GLP-1 Bridge?
You must have Medicare Part D coverage through a stand-alone drug plan or a Medicare health plan with drug coverage, be 18 or older, and have a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a or higher chronic kidney disease; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. You are not eligible if your Part D plan already covers a GLP-1 for you, or if you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, because your Part D plan may cover the drug for those conditions instead.
Does the $50 GLP-1 copay count toward the Part D out-of-pocket cap?
No. Medicare's fact sheet says the $50 payment does not count toward your drug plan's deductible or yearly out-of-pocket limit, and Bridge drugs cannot be spread out under the Medicare Prescription Payment Plan. The Part D cap is $2,100 in 2026 and $2,400 in 2027, and only drugs your plan covers count toward it. A year on the Bridge is $600 on top of whatever you pay for your other prescriptions.
How much will Ozempic cost with Medicare in 2027?
It depends on your plan, but the price underneath it falls. Ozempic, Rybelsus and Wegovy are among the drugs with a Medicare negotiated price starting January 1, 2027: $274 for a 30-day supply, against a 2024 list price of $959. Under the 2027 standard Part D benefit, a full year at that price would mean the $700 deductible and then 25% coinsurance, about $1,347, well under the $2,400 cap. Many plans use flat copays instead, so check your plan's 2027 formulary.
I don't have Part D. Can I still get GLP-1 drugs through Medicare?
Not through the Bridge, which requires Medicare drug coverage. During Open Enrollment, October 15 to December 7, 2026, you can join a stand-alone Part D plan or a Medicare Advantage plan with drug coverage for coverage starting January 1, 2027. If you went 63 or more days in a row without creditable drug coverage after you first became eligible, a Part D late enrollment penalty may apply for as long as you have Part D.
Sources
- Medicare.gov — Weight loss drugs (GLP-1 Bridge drugs, qualifying drug coverage, eligibility, provider requirements, prior authorization valid through December 31, 2027): medicare.gov/coverage/weight-loss-drugs
- Medicare.gov fact sheet — Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month, CMS Product No. 12234, June 2026 ($50 copay; not counted toward the deductible or out-of-pocket limit; not eligible for the Prescription Payment Plan; the four eligibility requirements): medicare.gov (PDF)
- CMS — Status Update on the BRIDGE Demo and BALANCE Model in Part D for CY2027, HPMS memo, April 21, 2026 (Bridge extended through December 31, 2027; BALANCE Part D delayed): cms.gov (PDF)
- CMS — CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications, press release, July 1, 2026: cms.gov/newsroom
- CMS — Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (Ozempic, Rybelsus, Wegovy $274 per 30-day supply vs. $959 list; package examples): cms.gov (PDF)
- Medicare.gov — Costs for Medicare drug coverage (2027 deductible up to $700; out-of-pocket threshold $2,400; 25% coinsurance): medicare.gov/health-drug-plans/part-d/basics/costs
- CMS — Medicare Part D Prescribers — by Geography and Drug, calendar years 2023 and 2024 (Utah and National rows for Ozempic, Mounjaro, Trulicity, Rybelsus, Wegovy): data.cms.gov … by-geography-and-drug
- CMS — Medicare Monthly Enrollment (average 2024 Part D enrollment: Utah 366,921, U.S. 54,375,198; Utah June 2026: 392,485 with drug coverage of 490,235): data.cms.gov … medicare-monthly-enrollment
- CDC — PLACES: Local Data for Better Health, County Data, 2025 release (measure OBESITY, crude prevalence, Utah counties and U.S. 32.8%): data.cdc.gov/…/swc5-untb
- Medicare.gov — Obesity behavioral therapy: medicare.gov/coverage/obesity-behavioral-therapy; Medicare Diabetes Prevention Program: medicare.gov/coverage/medicare-diabetes-prevention-program
- Utah Insurance Department — Medicare consumer page (Utah SHIP (877) 424-4640): insurance.utah.gov/consumers/health-insurance/medicare
About this article. Written by the Utah Retirement Income Data Desk and reviewed by Brian Penner, Retirement income & long-term care planner. Educational only — not medical, financial, or legal advice, and not a recommendation of any drug, plan or treatment; whether a GLP-1 medication is appropriate for you is a decision for you and your doctor. Program rules and prices are quoted from Medicare.gov and CMS as of October 16, 2026; the GLP-1 Bridge is a temporary demonstration that CMS can change, and its terms after December 31, 2027 have not been announced. Utah and national enrollee counts, shares and costs are our own tabulation of the CMS Part D Prescribers by Geography and Drug and Medicare Monthly Enrollment public use files, which CMS revises periodically; county obesity figures are CDC model-based estimates for all adults. Cost examples use the 2027 standard Part D benefit and the negotiated 30-day price and are illustrations, not price quotes; your plan's formulary, tier, copay or coinsurance, prior authorization rules and premium determine what you pay. Utah Retirement Income is a licensed independent insurance agency (NPN 16493717) and is not a government agency; we are not connected with or endorsed by Medicare, the Centers for Medicare & Medicaid Services, or any government program, and nothing here should be read as an endorsement by them. We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area; please contact Medicare.gov, 1-800-MEDICARE, or your State Health Insurance Assistance Program — in Utah, the Utah SHIP at (877) 424-4640 — to get information on all of your options. A $0-premium Medicare Advantage plan is not free; you still pay the Part B premium ($202.90 a month in 2026 for most people) and the plan's cost-sharing. Annuity guarantees depend on the claims-paying ability of the issuing company, with no promise of savings or returns. If you call or text us, you consent to be contacted at the number you provide about your options; message and data rates may apply, and you can opt out at any time by replying STOP.